Mark W. Hahn
2021 - Verona Pharma plc
In 2021, Mark W. Hahn earned a total compensation of $738.3K as Chief Financial Officer at Verona Pharma plc.
Compensation breakdown
| Non-Equity Incentive Plan | $218,875 |
|---|---|
| Salary | $402,500 |
| Stock Awards | $99,210 |
| Other | $17,704 |
| Total | $738,289 |
Hahn received $402.5K in salary, accounting for 55% of the total pay in 2021.
Hahn also received $218.9K in non-equity incentive plan, $99.2K in stock awards and $17.7K in other compensation.
Rankings
In 2021, Mark W. Hahn's compensation ranked 9,727th out of 12,415 executives tracked by ExecPay. In other words, Hahn earned more than 21.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,727 out of 12,415 | 22nd |
Division Manufacturing | 4,311 out of 5,505 | 22nd |
Major group Chemicals And Allied Products | 1,912 out of 2,375 | 20th |
Industry group Drugs | 1,697 out of 2,096 | 19th |
Industry Pharmaceutical Preparations | 1,262 out of 1,546 | 18th |
Source: SEC filing on March 21, 2023.
Hahn's colleagues
We found three more compensation records of executives who worked with Mark W. Hahn at Verona Pharma plc in 2021.